Generic Medicine Info
Should be taken on an empty stomach. Take 30 min before or 2 hr after meals.
Hypersensitivity to didanosine. Renal (CrCl <10 mL/min) impairment (delayed-release cap). Lactation. Concomitant use w/ allopurinol, ribavirin, stavudine, and hydroxyurea.
Special Precautions
Patient w/ history and risk of pancreatitis, history of neuropathy, hepatomegaly. Hepatic (e.g. chronic active hepatitis) and renal impairment. Childn. Pregnancy. Monitoring Parameters Monitor serum K, uric acid, creatinine, Hb, CBC w/ neutrophil and platelet count, CD4 cells, viral load, LFT, serum bilirubin, albumin, INR, amylase, wt gain. Monitor for signs and symptoms of peripheral neuropathy, hepatotoxicity, GI pain, and visual changes regularly during therapy. Perform dilated retinal exam every 6 mth.
Adverse Reactions
Significant: Peripheral neuropathy, immune reconstitution syndrome, fat redistribution (e.g. central obesity, peripheral and facial wasting, breast enlargement, buffalo hump, cushingoid appearance), osteonecrosis. Rarely, retinal changes (e.g. depigmentation), optic neuritis. Nervous: Headache, anxiety, insomnia, irritability, restlessness, seizures, fatigue, asthenia. CV: Increased risk of MI, cardiomyopathy. GI: Diarrhoea, nausea, vomiting, abdominal pain, anorexia, constipation, dyspepsia, dry mouth, flatulence, parotid gland enlargement, sialedenitis. Hepatic: Hepatitis, abnormal LFT. Endocrine: DM, hypo- and hyperglycaemia, hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperlactataemia, hyperuricaemia. Haematologic: Anaemia, leucopenia, thrombocytopenia. Musculoskeletal: Increased creatine phosphokinase, myalgia, arthralgia, myopathy, myositis, rhabdomyolysis. Ophthalmologic: Diplopia, dry eyes, optic atrophy, blindness. Dermatologic: Rash, alopecia, pruritus, mild erythematous macular eruption. Immunologic: Anaphylaxis. Others: Chills, fever, hypokalaemia, pain.
Potentially Fatal: Pancreatitis, lactic acidosis associated w/ hepatomegaly and steatosis. Rarely, noncirrhotic portal HTN, hepatic failure.
Drug Interactions
Decreased plasma concentration w/ methadone. Increased plasma concentration w/ ganciclovir and valganciclovir. Decreased effects of quinolones, tetracyclines, ketoconazole w/ buffered didanosine preparations. Increased risk of pancreatitis when used w/ pentamidine. Increased bioavailability of didanosine when concomitantly used w/ antacid.
CIMS Class
ATC Classification
J05AF02 - didanosine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on didanosine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in